The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review
Open accessAbstract
Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are stubborn inflammatory skin diseases categorized as neutrophilic hypodermal dermatoses. These conditions exhibit connections with other autoinflammatory disorders driven by immune responses. Their pathogenesis is complex, rooted in significant imbalances in both innate and adaptive immune systems, particularly featuring elevated levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1, IL-8, IL-17, and IL-23. Studies involving skin tissue pathology and serology have indicated that targeting specific cytokines can bring therapeutic benefits. Indeed, many patients in clinical settings have responded positively to such interventions. Yet, given the diverse cytokines in play, focusing on a single one with antibody therapy might not always be effective. When resistance to biologics emerges, a combined approach targeting multiple overactive cytokines with immunosuppressants, for example cyclosporine and Janus kinase inhibitors, could be an option. In the current review, we explore recent therapeutic developments for PG and HS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In advanced diseases with tunnel formation and fibrosis, surgical management remains essential, often combined with medical therapy to control inflammation and prevent recurrence [40,44,45,46,47].”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [46]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Vitiligo is an immune-mediated disease characterized by the destruction of melanocytes.”
From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
Kimball, A. B., Okun, M. M., Williams, D., Gottlieb, A. B., Papp, K. A., Zouboulis, C. C., Armstrong, A. W., Kerdel, F. A., Gold, M. H., Forman, S. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504370 · Cited by 813
Hidradenitis suppurativa: A comprehensive review
Alikhan, A., Lynch, P., & Eisen, D. B. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.911 · Cited by 708
Brooklyn, T., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S. (2005) · Gut · doi:10.1136/gut.2005.074815 · Cited by 647
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 473
Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines
Henry, C. M., Sullivan, G. P., Clancy, D. M., Afonina, I. S., Kulms, D., & Martin, S. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.072 · Cited by 330
Maverakis, E., Marzano, A. V., Le, S. T., Callen, J. P., Brüggen, M., Guenova, E., Dissemond, J., Shinkai, K., & Langan, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0213-x · Cited by 322
Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
Kelly, G. A., Hughes, R., McGarry, T., Born, M., Adamzik, K., Fitzgerald, R., Lawlor, C., Tobin, A., Sweeney, C. M., & Kirby, B. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14075 · Cited by 312
Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands
Yu, C. C. W., & Cook, M. G. (1990) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1990.tb06264.x · Cited by 304
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa
Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., Dinarello, C. A., van der Meer, J. W. M., Rigopoulos, D., & Giamarellos‐Bourboulis, E. J. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.3903 · Cited by 268
Cited by
Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026) · Dermatopathology · doi:10.3390/dermatopathology13020022 · Cited by 1
“Although several aspects remain unclear, immune mechanisms are central to vitiligo pathogenesis [46].”
Metadata
- Authors
- Yamanaka, K.
- Affiliations
- Mie University (JP)
- Corresponding author
- Yamanaka, Keiichi
- ORCID
- Yamanaka, Keiichi
- Venue
- The Journal of Dermatology
- Publisher
- Wiley
- Published
- 2023-11-27
- Volume
- 51
- Issue
- 2
- Pages
- 172-179
- ISSN
- 0385-2407 (ISSN-L)
- 1346-8138
- PMC
- PMC11483966
- OpenAlex
- W4389069982
- Cited by
- 19
- References
- 93
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 5
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Dermatology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Autoimmune and Inflammatory Disorders
- Health Sciences › Medicine › Dermatology › Hidradenitis Suppurativa and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- pyoderma gangrenosum, hidradenitis suppurativa, cytokine therapy, TNF-α, interleukin-1, IL-17, IL-23, interleukin-8, JAK inhibitors, cyclosporine, immunosuppressants, autoinflammatory skin disease
- MeSH terms
- Dermatitis, Humans, Skin, Cytokines, Hidradenitis Suppurativa, Pyoderma Gangrenosum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
